Phase IB Sample Clauses
Phase IB. Promptly upon notification by SGX to the JSC that it has completed the Phase IB validation, Lilly, in consultation with the JSC, shall determine in good faith whether such validation satisfies the Phase IB Acceptance Criteria. Upon the determination by Lilly of achievement of the Phase 1B Acceptance Criteria but in no event later than the end of the Term of the Research Collaboration, SGX will assign to Lilly its entire right, title and interest in and to the Platform components procured by SGX on behalf of Lilly under Section 3.2(a), installed at the Lilly San Diego Facility, including without limitation, assignment of Third Party warranties and service contracts where permitted.
Phase IB. The period during which the following activities are performed: decontamination, dismantling, and disposal or final disposition of all contaminated and non-contaminated onshore and offshore nuclear site equipment, components, buildings, structures, and foundations, except for equipment, components, buildings, structures and foundations left in place until Phase II or final Site Restoration; the surveying and documentation of the radiological and environmental status of the Project Land Areas; and preparation for Phase II.
Phase IB. Phase Ib * * Payments Gross Margin Calculation
Phase IB. Humanized Antibody; Verification; Minimum Anti-HIV Activity. Promptly following delivery of the Humanized Antibody pursuant to Section 2.02(a), PROGENICS shall also evaluate the Humanized Antibody to determine whether such antibody also possesses anti-HIV activity not less than one-third (1/3) that of the Murine Antibody (“Minimum Anti-HIV Activity”) as measured according to an HIV-1 infectivity assay that measures the extent of HIV-l replication specified in ▇▇▇▇▇▇ et. al., Journal of Virology, 72:396, 1998. In the event that the supplied Humanized Antibody does not meet both the Minimum Binding Affinity and the Minimum Anti-HIV Activity or is, in PROGENICS’ sole discretion, not sufficiently close thereto to proceed with development, PROGENICS shall promptly inform PDL accordingly in writing. PDL shall then use commercially reasonable efforts to produce another Humanized Antibody in an effort to achieve the Minimum Binding Affinity and the Minimum Anti-HIV Activity. PROGENICS acknowledges and agrees that achievement of the Minimum Biological Activity may require use of another IgG isotype, which isotype shall be reasonably acceptable to PROGENICS. In any event, the quantity of Humanized Antibody required by PROGENICS for evaluation under Phase IA and IB shall not exceed approximately 5 mg in the aggregate. In the event that the second Humanized Antibody does not meet the Minimum Binding Activity and the Minimum Anti-HIV Activity or is, in PROGENICS’ sole discretion, not sufficiently close thereto to enable PROGENICS to proceed with development, then the parties shall consult in good faith in order to determine how to proceed with further development. In the event that PROGENICS determines that one of the Humanized Antibodies provided by PDL meets the Minimum Binding Affinity and the Minimum Anti-HIV Activity, or is sufficiently close thereto to enable PROGENICS to proceed with the Humanized Antibody under Phase II of the Program, it shall promptly notify PDL in writing (the “Phase I Completion Notice”). At the completion of Phase I, if requested by PROGENICS, PDL will deliver a sample of (i) a non-optimized cell line and (ii) a DNA vector (“DNA Vector”) producing the Humanized Antibody to allow PROGENICS to conduct research while PDL proceeds with Phase II of the Program.
Phase IB. The Contractor shall develop participant workbooks and instructor's lesson plans. The participant's workbook should include useful summaries of lecture material and reltvant reference information. The Instructor's Lesson Plans shall be written with clarity and sufficient detail so~ that instructors, familiar with regulation, can depend upon tne lesson Plans to implement this NRC course.